FDA Grants Priority Review to Nirogacestat for Desmoid Tumors

Article

Findings from the phase 3 DeFi trial support the new drug application for nirogacestat as a treatment for adults with desmoid tumors.

The FDA has accepted and granted priority review to an investigational new drug application for nirogacestat as a treatment for adult patients with desmoid tumors, according to a press release from SpringWorks Therapeutics.1

"The acceptance of our [new drug application] for nirogacestat with priority review represents a significant milestone in our ambition to provide the first approved therapy for patients with desmoid tumors," according to the manufacturers of nirogacestat.

"The acceptance of our [new drug application] for nirogacestat with priority review represents a significant milestone in our ambition to provide the first approved therapy for patients with desmoid tumors," according to the manufacturers of nirogacestat.

The FDA has set a Prescription Drug User Fee Act date for August 27, 2023.

The investigational new drug application was supported by data from the phase 3 DeFi trial (NCT03785964), which read out at the 2022 European Society for Medical Oncology Congress (ESMO).

In the DeFi trial, the median progression-free survival (PFS) was not reached with nirogacestat compared with 15.1 months in the placebo arm; the former demonstrated a 71% reduction in the risk of disease progression (HR, 0.29; 95% CI, 0.15-0.55; P <.001).2 Additionally, nirogacestat yielded a PFS benefit across all prespecified subgroups based on factors such as gender, tumor location, prior treatment or surgery, and mutational status.

“The acceptance of our [new drug application] for nirogacestat with priority review represents a significant milestone in our ambition to provide the first approved therapy for patients with desmoid tumors,” Saqib Islam, chief executive officer at SpringWorks, said in the press release.

Investigators of the global, randomized, double-blind, placebo-controlled phase 3 DeFi trial compared the efficacy and safety of nirogacestat with placebo in adult patients with progressing desmoid tumors. A total of 142 patients were randomly assigned 1:1 to either receive 150 mg of nirogacestat (n =70) or placebo (n = 72) twice a day.

The primary end point of the trial was PFS as assessed by blinded independent central review. Secondary and exploratory end points included safety, objective response rate (ORR), duration of response, changes in tumor volume, and patient-reported outcomes.

Patients 18 years and older with histologically confirmed desmoid tumors that have progressed by at least 20% per RECIST v1.1 guidelines within 12 months of screening were eligible for enrollment. Additional inclusion criteria included having provided archival or new tumor tissue for reconfirmation of disease, an ECOG performance status of 2 or lower, and adequate organ and bone marrow function.

Confirmed ORR in the DeFi trial was 41% with nirogacestat vs 8% with placebo (P <.001), with complete response rates of 7% vs 0%. Additionally, nirogacestat produced statistically significant and clinically meaningful improvements in patient-reported outcomes including pain reduction (P <.001), other desmoid tumor-specific symptoms (P <.001), improved physical role functioning (P <.001), and overall health-related quality of life (P = .007).

Overall, 95% of treatment-emergent adverse effects (TEAEs) following nirogacestat therapy were grade 1 or 2. The most frequent TEAEs in the nirogacestat and placebo arms, respectively, included diarrhea (84% vs 35%), nausea (54% vs 39%), and fatigue (51% vs 36%). In each respective arm, dose reductions due to TEAEs occurred in 42% vs 0%, and treatment discontinuation due to TEAEs was necessary in 20% vs 1%, respectively.

Investigators observed ovarian dysfunction in 75% (n = 27/36) of patients of childbearing potential who received nirogacestat. Of these patients, 74% had their AEs resolve, including 64% who remained on nirogacestat treatment.

References

  1. SpringWorks Therapeutics announces FDA acceptance and priority review of new drug application for nirogacestat for the treatment of adults with desmoid tumors. News release. SpringWorks Therapeutics. February 27, 2023. Accessed February 27, 2023. bit.ly/3SxA1Qk
  2. SpringWorks Therapeutics announces data from phase 3 DeFi trial evaluating nirogacestat in adult patients with progressing desmoid tumors at the European Society for Medical Oncology (ESMO) Congress 2022. News release. September 10, 2022. Accessed February 27, 2023. bit.ly/3YWB2Ux
Related Videos
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.
Related Content
Striving for Health Care Equity by Closing the Cancer Care Gap

Striving for Health Care Equity by Closing the Cancer Care Gap

April 18th 2024
Article

“If you were to ask me what the 1 magic thing would be, it would be that we would adopt a concept of 1 team, one fight nationally, and that we would be able to have our structures and our coordination of care.”

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Creating a First-of-Its-Kind Integrative Oncology Program at City of Hope

March 18th 2024
Podcast

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.

FDA Grants Accelerated Approval to T-DXd in Advanced HER2+ Solid Tumors

April 5th 2024
Article

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

Addressing Rising Cancer Incidence and Burden in Younger Populations

March 11th 2024
Podcast

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

An updated guideline from ASCO highlights appropriate use of vaccines for patients with cancer receiving treatments such as CAR T-cell therapy or B-cell depleting therapy.

Updated ASCO Guideline Issues Vaccine Recommendations in Cancer Populations

March 31st 2024
Article

An updated guideline from ASCO highlights appropriate use of vaccines for patients with cancer receiving treatments such as CAR T-cell therapy or B-cell depleting therapy.

Investigators will evaluate the preliminary efficacy and safety of NST-628 in adult patients with solid tumors harboring mutations in the RAS-MAPK pathway as part of a phase 1 trial.

FDA Clears IND for Novel Molecular Glue in Advanced Solid Tumors

March 29th 2024
Article

Investigators will evaluate the preliminary efficacy and safety of NST-628 in adult patients with solid tumors harboring mutations in the RAS-MAPK pathway as part of a phase 1 trial.